NEW YORK – Women's health personalized medicine company DotLab said on Monday it has secured $10 million in Series A funding.
The San Francisco-based firm is combining noninvasive microRNA biomarkers with machine learning to develop a noninvasive test for endometriosis. In a statement, DotLab CEO Heather Bowerman said that the company will use the funds to "further clinical validation, expand market access, and continue to grow our team."
CooperSurgical, a business unit of The Cooper Companies, led the financing, which also included individual investors from Tiger Global Management, Luxor Capital Group, and the law firm Wilson Sonsini Goodrich & Rosati.
The DotLab test detects microRNA biomarkers, but it is not a genetic test for endometriosis, and the risk profiles do not confirm active disease, Bowerman said in an email.